Failed IVF

At Laimaa Healthcare, fertility specialists often meet couples who ask whether immune testing can explain repeated IVF failure. In the last few years, immune testing has quietly entered fertility clinics—not with loud promises, but with soft reassurance. A blood test here, a panel there, and a suggestion that maybe the immune system is the hidden reason behind repeated IVF failure. Patients rarely come asking for immune tests on day one. They come after two failed transfers—sometimes after three. Often, after they have already done everything that standard IVF medicine advises. At that moment, immune testing looks attractive. It looks scientific. It looks like progress. But the real question is not whether immune testing can detect something abnormal. The real question is: Can immune testing actually predict IVF failure in a way that changes the outcome? The Uncomfortable Reality About IVF Failure Most IVF failures are still explained by only two large factors: Even today, after advanced genetics, better culture systems and improved stimulation protocols, implantation remains inefficient. And when no obvious problem appears in scans, hormone levels or embryo reports, the word “immune” quietly enters the discussion. Not because the immune system is irrelevant. But because it is complex, powerful and poorly measurable inside the uterus. The First Problem: What Exactly Is “Immune Testing” In IVF? There is no single immune test. In routine fertility practice, immune testing usually refers to combinations of: The problem is not that these tests exist. The problem is that they are borrowed from autoimmune and transplant medicine and placed into reproductive medicine without strong validation for implantation failure. That difference is not small. It changes everything. Blood Immunity And Uterine Immunity Are Not The Same System This is rarely explained clearly to patients. Most immune tests are done on blood. Implantation, however, happens inside a very specialised tissue – the endometrium. The immune cells that matter most during implantation are: Peripheral blood NK cells behave very differently from uterine NK cells. They have different surface markers. They respond to different signals. They perform different functions. So when a report shows “high NK activity” in blood, it does not directly tell what is happening at the embryo–endometrium interface. This gap is not small. It is biological. Why Immune Testing Feels Convincing After Repeated Failures Repeated failure changes the psychology of treatment. After several good-quality embryos fail to implant, patients and clinicians both want a new explanation. Immune testing offers something that routine IVF evaluation cannot: A new variable. Not necessarily a correct one, but a new one. And new variables feel like progress. But Prediction Is Different From Explanation This is where the discussion must become honest. Immune testing is often presented as: “Let us see whether immunity is the reason for failure.” But the patient really wants something else: can this test tell me whether my next IVF will fail? That is a prediction. And this is where immune testing performs poorly. The Biggest Weakness: Immune Markers Are Unstable One of the least discussed problems is biological variability. Immune markers change with: A patient can test “high” today and “normal” next month without any intervention. Yet clinical decisions are sometimes taken based on a single snapshot. This makes the prediction unreliable. IVF Failure Is Not An Immune Event Alone Implantation is not a simple accept–reject mechanism. It is a synchronised process involving: The immune system does not initiate implantation. It fine-tunes it. When something fails, immune disturbance may be a downstream effect rather than the primary cause. This distinction is critical. Can Immune Testing Ever Predict IVF Failure? If we answer strictly and clinically: No immune test today can reliably predict IVF failure in an individual patient. Not with the accuracy that justifies routine use. Not with reproducibility across populations. Not with validated thresholds. But Is Immune Involvement Completely Irrelevant? No. That would also be incorrect. There are limited situations where immune evaluation is relevant: In these contexts, the immune issue is already clinically evident. It is not discovered through screening panels done only for IVF. The Confusion Between Miscarriage And Implantation Failure Another important misunderstanding. Most immune research is stronger in pregnancy loss, not implantation failure. These are biologically different stages. The immune mechanisms that maintain an established placenta are not identical to those involved in early attachment. Yet many immune tests are marketed for implantation failure using evidence from miscarriage populations. This is a serious extrapolation problem. A Better Way To Look At Unexplained IVF Failure From a modern clinical angle, unexplained failure is increasingly viewed as: These areas, although less dramatic than immune theory, consistently show stronger links to outcome. Also read: Low Egg Count: Can I Still Get Pregnant?  Where Research Is Actually Moving Interestingly, serious research is not focused on peripheral immune panels. It is moving towards: These approaches aim to understand micro-environmental communication rather than broad systemic immunity. But none of this is clinically deployable yet. Prediction models based on these technologies are still under development. The Commercialisation Risk Immune testing has entered a difficult space. It remains between: Patients often assume that if a test is offered, it must be validated for that purpose. In reality, laboratory availability does not equal clinical validity. So, what is the correct role of immune testing today? At present, immune testing should be: It should not be positioned as a standard next step after two failed transfers. Conclusion  At Laimaa Healthcare, the focus remains on evidence-based fertility treatment, personalised IVF planning, and improving cumulative success rates rather than relying on poorly predictive immune panels. IVF medicine is already complex. Adding poorly predictive tools increases complexity without improving clarity. The focus should remain on cumulative success strategies, laboratory excellence, embryo competence assessment, and patient-specific stimulation and transfer planning. Until immune science moves from associative findings to precise, targetable mechanisms at the implantation site, immune testing will remain more exploratory than predictive. That distinction matters. For patients investing emotionally, physically and financially into every cycle, what matters most is not whether a